Barros Oriana, D'Agostino Vito Giuseppe, Santos Lucio, Ferreira Rita, Vitorino Rui
Department of Medical Sciences, Institute of Biomedicine iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal.
Experimental Pathology and Therapeutics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Surgical Department of Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto. CCC), 4200-072 Porto, Portugal.
Biomedicines. 2024 Feb 27;12(3):529. doi: 10.3390/biomedicines12030529.
Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with a poor prognosis. Galectins (Gal) have been the subject of intensive research, but the comparative prognostic value of each Gal type is not yet understood. Therefore, a literature search for evaluating galectins as prognostic biomarkers in HNSCC was conducted. The relationship between Gal expression in HNSCC with HPV and mutational status was assessed using the UALCAN database. The impact of these biomarkers on prognosis was analyzed using ToPP and CPPA web tools. The expression of galectins in the tumor microenvironment and the impact on prognosis depending on the cancer immune subtype were analyzed using single-cell RNA sequencing. and were shown to be promising biomarkers with a triple function for the prediction of HPV and mutational status, stratification of the HNSCC prognosis, and prediction of the response to treatment. In addition, these two galectins have been shown to be most influenced by the tumor microenvironment of HNSCC. and are the most promising galectins in HNSCC. Furthermore, this study highlights the need for further studies to evaluate galectins in HNSCC and clarify the role of individual Gals in the patient's stratification.
头颈部鳞状细胞癌（HNSCC）是一种预后较差的恶性肿瘤。半乳糖凝集素（Gal）一直是深入研究的对象，但每种Gal类型的比较预后价值尚不清楚。因此，我们进行了一项文献检索，以评估半乳糖凝集素作为HNSCC预后生物标志物的情况。使用UALCAN数据库评估HNSCC中Gal表达与HPV和突变状态之间的关系。使用ToPP和CPPA网络工具分析这些生物标志物对预后的影响。使用单细胞RNA测序分析肿瘤微环境中半乳糖凝集素的表达以及根据癌症免疫亚型对预后的影响。结果表明， 和 是具有三重功能的有前景的生物标志物，可用于预测HPV和突变状态、对HNSCC预后进行分层以及预测治疗反应。此外，这两种半乳糖凝集素已被证明受HNSCC肿瘤微环境的影响最大。 和 是HNSCC中最有前景的半乳糖凝集素。此外，本研究强调需要进一步研究以评估HNSCC中的半乳糖凝集素，并阐明个体Gal在患者分层中的作用。
